MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth is viewed favorably because it has been streamlined into a focused prostate cancer diagnostics business after the Resolve wind-down, removing the $10.4M Novitas claim and a meaningful liability overhang while sharpening commercial execution around three core products. The company also strengthened its balance sheet with a $20M registered direct offering, lifting pro forma cash to about $39 million, while the acquired ExoDx franchise is expected to add $20M+ of annual revenue and support a revenue base that reached about $108M in 2025. Fundamentally, the outlook is positive because the business is exposed to a large and underdiagnosed PSA-driven market, benefits from guideline support and secular urology growth, and has a path to positive Adjusted EBITDA in Q4'26 and roughly 20% margin by exiting 2028.

MDxHealth is facing a negative fundamental reset because the Resolve UTI discontinuation removes a meaningful revenue stream that was roughly 16% of sales and had grown above the corporate average, while the company simultaneously faces a $10.4M recoupment demand from Novitas tied to historical payments. Its Q1'26 results already showed strain, with revenue of $27.4M missing estimates, adjusted EBITDA of -$4.3M, and pro-forma cash of $28.2M, underscoring limited operating leverage and ongoing cash pressure. Management’s narrowed focus on GPS, ConfirmMDx, and ExoDx may improve discipline, but the steep 2026 revenue guide cut to $110-115M from $137-140M highlights a smaller, more uncertain growth base.